Biogen Q1 2026 EPS $3.57 on $2.5B revenue beats forecasts as full-year EPS outlook cut on IPR&D charges

 

Biogen Q1 2026 EPS $3.57 on $2.5B revenue beats forecasts as full-year EPS outlook cut on IPR&D charges

• GAAP EPS increased 31% year over year in Q1 2026, while revenue reached $2.5B.
• Biogen trimmed 2026 full-year EPS guidance to $14.25–$15.25 from $15.25–$16.25.
• Biogen disclosed the Q1 2026 results and updated full-year guidance in a recent SEC filing.

https://finviz.com/quote?t=BIIB&p=d